RECENT PAST NEWS IN MDR-TB

2022 Updates to Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd ed.

WHO announces landmark changes in treatment of drug-resistant TB!

Price reduction paves the way for expanded access to highly effective MDR-TB

Public Health Leaders, Researchers, and Activists Launch Campaign to Revolutionize Tuberculosis

New testing method could make TB diagnosis easier

Drug-Resistant TB Trial Results Published in New England Journal of Medicine

MSF warns that supply delays of critical TB test will cost lives

1 / 4 / 6 x 24 Campaign launched to rally energy, political will, funding needed to fight TB

PAN-TB collaboration to advance investigational TB drug regimens to Phase 2 clinical trials

Sequencing effort aims to improve drug-resistant TB diagnosis, treatment

New blood test can help doctors diagnose TB and monitor treatment

WHO issues rapid communication on updated guidance for the treatment of drug-resistant tuberculosis

20% of multi-drug resistant tuberculosis cases in children could be averted by household testing

Rise of drug-resistant tuberculosis is hidden in plain sight

Updated WHO 6-Month MDR-TB Regimen

Possible new method identified to assess severity of TB infection

Drug-resistant TB: Rollout of shorter regimen hits a snag in South Africa

Promising new target for tuberculosis treatment

Genomic signatures of pre-resistance in Mycobacterium tuberculosis

New TB Funding Trends Report Finds that Funding for TB Research in 2020 Reached Only US$915 Million